[{"id":"b38928cb-8505-433c-80c6-0b0f9c9ff90b","acronym":"SHR-A1904-I-104","url":"https://clinicaltrials.gov/study/NCT05277168","created_at":"2023-01-18T16:59:24.432Z","updated_at":"2025-02-25T14:16:45.234Z","phase":"Phase 1/2","brief_title":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","source_id_and_acronym":"NCT05277168 - SHR-A1904-I-104","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e garetatug rezetecan (SHR-A1904)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 03/03/2026","primary_completion_date":" 03/03/2026","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2025-02-17"}]